Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study

被引:56
|
作者
Walker, Venexia M. [1 ,2 ]
Kehoe, Patrick G. [3 ,4 ]
Martin, Richard M. [1 ,2 ]
Davies, Neil M. [1 ,2 ]
机构
[1] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Bristol, Avon, England
[2] Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol, Avon, England
[3] Univ Bristol, Dementia Res Grp, Bristol, Avon, England
[4] Univ Bristol, Bristol Med Sch Translat Hlth Sci, Bristol, Avon, England
基金
英国医学研究理事会;
关键词
Mendelian randomization; drug repurposing; Alzheimer's disease; hypertension; antihypertensive drugs; BLOOD-PRESSURE; INSTRUMENTS; RISK;
D O I
10.1093/ije/dyz155
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease. Methods: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. Results: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p= 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p= 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p= 0.45; SNPs = 153). Conclusions: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.
引用
收藏
页码:1132 / 1140
页数:9
相关论文
共 50 条
  • [31] Using Mendelian randomization study to assess the renal effects of antihypertensive drugs
    Zhao, Jie V.
    Schooling, C. Mary
    BMC MEDICINE, 2021, 19 (01)
  • [32] Amyloid, tau and risk of Alzheimer's disease: a Mendelian randomization study
    Yeung, Chris Ho Ching
    Lau, Kathleen Wen Din
    Au Yeung, Shiu Lun
    Schooling, C. Mary
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2021, 36 (01) : 81 - 88
  • [33] Dietary factors and Alzheimer's disease risk: a Mendelian randomization study
    Meng, Qi
    Chen, Chen
    Zhu, Mingfang
    Huang, Yue
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01) : 261
  • [34] White Matter and Alzheimer's Disease: A Bidirectional Mendelian Randomization Study
    Li, Yaqing
    Zheng, Jiaxin
    Li, Tian
    Zhang, Junjian
    NEUROLOGY AND THERAPY, 2022, 11 (02) : 881 - 892
  • [35] Using Mendelian randomization study to assess the renal effects of antihypertensive drugs
    Jie V. Zhao
    C. Mary Schooling
    BMC Medicine, 19
  • [36] Effect of the Blood Pressure and Antihypertensive Drugs on Cerebral Small Vessel Disease: A Mendelian Randomization Study
    Ma, Yazhou
    Wang, Mengmeng
    Chen, Xin
    Yao, Jianrong
    Ding, Yiping
    Gao, Qianqian
    Zhou, Jiayi
    Lian, Xuegan
    STROKE, 2024, 55 (07) : 1838 - 1846
  • [37] Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk A Mendelian Randomization Study
    Tang, Bowen
    Wang, Yunzhang
    Jiang, Xia
    Thambisetty, Madhav
    Ferrucci, Luigi
    Johnell, Kristina
    Hagg, Sara
    NEUROLOGY, 2022, 99 (07) : E650 - E659
  • [38] Systematic review of Mendelian randomization studies on antihypertensive drugs
    Fan, Bohan
    Zhang, Junmeng
    Zhao, Jie V.
    BMC MEDICINE, 2024, 22 (01):
  • [39] Polyunsaturated fatty acids and risk of Alzheimer's disease: a Mendelian randomization study
    Tomata, Yasutake
    Larsson, Susanna C.
    Hagg, Sara
    EUROPEAN JOURNAL OF NUTRITION, 2020, 59 (04) : 1763 - 1766
  • [40] The role of Immune cells in Alzheimer's disease: a bidirectional Mendelian randomization study
    Zhang, Erdong
    Chen, Tingting
    Chen, Yanqin
    Long, Chenxiang
    Tao, Ling
    Shen, Xiangchun
    Dai, Fengqiu
    FRONTIERS IN AGING NEUROSCIENCE, 2024, 16